ArticleJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2024
No differences in native T1 of the renal cortex between Fabry disease patients and healthy subjects in cardiac-dedicated native T1 maps.
Article in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFabry disease (FD) is an X-linked inherited lysosomal storage disease that is caused by deficient activity of the enzyme alpha-galactosidase A. Cardiovascular magnetic resonance (CMR) imaging can detect cardiac sphingolipid accumulation using native T1 mapping. The kidneys are often visible in cardiac CMR native T1 maps; however, it is currently unknown if the maps can be used to detect sphingolipid accumulation in the kidneys of FD patients. Therefore, the aim of this study was to evaluate if cardiac-dedicated native T1 maps can be used to detect sphingolipid accumulation in the kidneys.
methodsFD patients (n = 18, 41 ± 10 years, 44% (8/18) male) and healthy subjects (n = 38, 41 ± 16 years, 47% (18/38) male) were retrospectively enrolled. Native T1 maps were acquired at 1.5T using modified Look-Locker inversion recovery research sequences. Native T1 values were measured by manually delineating regions of interest (ROI) in the renal cortex, renal medulla, heart, spleen, blood, and liver. Endo- and epicardial borders were delineated in the myocardium and averaged across all slices. Blood ROIs were placed in the left ventricular blood pool in the midventricular slice.
resultsThere were no differences in native T1 between the FD patients and the healthy subjects in the renal cortex (1034 ± 88 ms vs 1056 ± 59 ms, p = 0.29), blood (1614 ± 111 ms vs 1576 ± 100 ms, p = 0.22), spleen (1143 ± 45 ms vs 1132 ± 70 ms, p = 0.54), or liver (568 ± 49 ms vs 557 ± 47 ms, p = 0.41). Native myocardial T1 was lower in FD patients compared to healthy subjects (951 ± 79 vs 1006 ± 38, p<0.01), and higher in the renal medulla (1635 ± 144 vs 1514 ± 81, p<0.01).
conclusionCompared to healthy subjects, patients with FD and cardiac involvement showed no differences in native T1 of the renal cortex. FD patients had higher native T1 in the renal medulla, which is not totally explained by differences in blood native T1 but may reflect a hyperfiltration state in the development of renal failure. The findings suggest that sphingolipid accumulation in the renal cortex in FD patients could not be detected with cardiac-dedicated research native T1 maps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.